# MCKESSON CORP (MCK)

Informational only - not investment advice.

CIK: 0000927653
SIC: 5122 Wholesale-Drugs, Proprietaries & Druggists' Sundries
SIC breadcrumb: [Wholesale Trade](/division/F/) > [Wholesale Trade - Nondurable Goods](/major-group/51/) > [SIC 5122 Wholesale-Drugs, Proprietaries & Druggists' Sundries](/industry/5122/)
Latest 10-K filed: 2026-05-08
SEC page: https://www.sec.gov/edgar/browse/?CIK=927653
Filing source: https://www.sec.gov/Archives/edgar/data/927653/000092765326000069/mck-20260331.htm

## At a glance

FY2026 · period end 2026-03-31 · filed 2026-05-08 · accession 0000927653-26-000069 · source: https://data.sec.gov/api/xbrl/companyfacts/CIK0000927653.json

| Metric | Value | FY | Provenance |
| --- | ---: | ---: | --- |
| Revenue | 403,430,000,000 USD | 2026 | verified |
| Net income | 4,762,000,000 USD | 2026 | verified |
| Assets | 82,323,000,000 USD | 2026 | verified |
| Free cash flow | 5,719,000,000 USD | 2026 | computed |
| Net margin | 1.18% | 2026 | computed |
| Operating margin | 1.54% | 2026 | computed |
| Revenue YoY | +12.36% | 2026 | computed |

Stockholders' equity was not positive at FY2026 year-end (-2,172,000,000 USD, as filed); ROE and liabilities / equity are omitted rather than computed.

Computed values are grepcent-computed from the verified facts above and may differ from ratios the company itself reports. Free cash flow = operating cash flow − capital expenditures. Net margin = net income ÷ revenue. Operating margin = operating income ÷ revenue. Revenue YoY = FY2026 revenue ÷ FY2025 revenue − 1 (consecutive fiscal years only).

Peer groups: [Pharmaceutical distributors](/compare/drug-distributors/) · SIC 5122 Wholesale-Drugs, Proprietaries & Druggists' Sundries

No market price, no rating, no forecast on this site. Not investment advice.

## Peer comparisons including MCK

- Pharmaceutical distributors: [peer review](/compare/drug-distributors/) · [market-risk page](/compare/drug-distributors/risk/)

### Peer percentile fingerprint

| Ratio | MCK | Peer median | Percentile | N |
| --- | ---: | ---: | ---: | ---: |
| Net margin | 1.2% | 1.2% | 52 | 22 |
| Operating margin | 1.5% | 2.5% | 40 | 21 |
| Revenue growth | 12.4% | 2.4% | 95 | 22 |
| FCF margin | 1.4% | 2.0% | 33 | 22 |
| ROA | 5.8% | 3.3% | 67 | 22 |
| Current ratio | 0.85 | 1.58 | 0 | 22 |

Percentile = share of the N covered peers reporting that ratio whose value is lower (ties counted half); computed among grepcent-covered companies in SIC major-group 51 Wholesale Trade - Nondurable Goods, not the whole market. A higher percentile means a higher value of the ratio, not a better company. Ratios with fewer than 8 reporting peers are omitted. Latest reported values per company; fiscal periods may differ. Descriptive arithmetic - not a score, rating, or ranking.

## Selected Fundamentals
| Metric | Value | Unit | FY | Filed |
| --- | ---: | --- | ---: | --- |
| Revenue | 403430000000 | USD | 2026 | 2026-05-08 |
| Net income | 4762000000 | USD | 2026 | 2026-05-08 |
| Assets | 82323000000 | USD | 2026 | 2026-05-08 |

## Financials

Annual standardized facts from SEC companyfacts as of latest extracted filing date 2026-05-08. Source: https://data.sec.gov/api/xbrl/companyfacts/CIK0000927653.json. Derived margins, ratios, and free cash flow are computed from the extracted annual SEC facts.

| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | 198,533,000,000 | 208,357,000,000 | 214,319,000,000 | 231,051,000,000 | 238,228,000,000 | 263,966,000,000 | 276,711,000,000 | 308,951,000,000 | 359,051,000,000 | 403,430,000,000 |
| Net income | 5,070,000,000 | 67,000,000 | 34,000,000 | 900,000,000 | -4,539,000,000 | 1,114,000,000 | 3,560,000,000 | 3,002,000,000 | 3,295,000,000 | 4,762,000,000 |
| Operating income | 7,122,000,000 | 762,000,000 | 886,000,000 | 2,489,000,000 | -5,040,000,000 | 2,038,000,000 | 4,381,000,000 | 3,909,000,000 | 4,422,000,000 | 6,212,000,000 |
| Gross profit | 11,271,000,000 | 11,184,000,000 | 11,754,000,000 | 12,023,000,000 | 12,148,000,000 | 13,130,000,000 | 12,358,000,000 | 12,828,000,000 | 13,323,000,000 | 14,550,000,000 |
| Diluted EPS | 22.73 | 0.32 | 0.17 | 4.95 | -28.26 | 7.23 | 25.03 | 22.39 | 25.72 | 38.38 |
| Operating cash flow | 4,744,000,000 | 4,345,000,000 | 4,036,000,000 | 4,374,000,000 | 4,542,000,000 | 4,434,000,000 | 5,159,000,000 | 4,314,000,000 | 6,085,000,000 | 6,155,000,000 |
| Capital expenditures | 404,000,000 | 405,000,000 | 426,000,000 | 362,000,000 | 451,000,000 | 388,000,000 | 390,000,000 | 431,000,000 | 537,000,000 | 436,000,000 |
| Dividends paid | 253,000,000 | 262,000,000 | 292,000,000 | 294,000,000 | 276,000,000 | 277,000,000 | 292,000,000 | 314,000,000 | 345,000,000 | 381,000,000 |
| Share buybacks | 2,311,000,000 | 1,709,000,000 | 1,639,000,000 | 1,934,000,000 | 742,000,000 | 3,516,000,000 | 3,638,000,000 | 3,025,000,000 | 3,146,000,000 | 4,750,000,000 |
| Assets | 60,969,000,000 | 60,381,000,000 | 59,672,000,000 | 61,247,000,000 | 65,015,000,000 | 63,298,000,000 | 62,320,000,000 | 67,443,000,000 | 75,140,000,000 | 82,323,000,000 |
| Stockholders' equity | 11,095,000,000 | 9,804,000,000 | 8,094,000,000 | 5,092,000,000 | -21,000,000 | -2,272,000,000 | -1,857,000,000 | -1,971,000,000 | -2,074,000,000 | -2,172,000,000 |
| Cash and cash equivalents | 2,783,000,000 | 2,672,000,000 | 2,981,000,000 | 4,015,000,000 | 6,278,000,000 | 3,532,000,000 | 4,678,000,000 | 4,583,000,000 | 5,691,000,000 | 3,975,000,000 |
| Free cash flow | 4,340,000,000 | 3,940,000,000 | 3,610,000,000 | 4,012,000,000 | 4,091,000,000 | 4,046,000,000 | 4,769,000,000 | 3,883,000,000 | 5,548,000,000 | 5,719,000,000 |

### Ratios

ROE and ROA use period-end equity/assets. Liabilities / equity uses total liabilities divided by stockholders' equity. Current ratio uses current assets divided by current liabilities when both are reported.

| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Net margin | 2.55% | 0.03% | 0.02% | 0.39% | -1.91% | 0.42% | 1.29% | 0.97% | 0.92% | 1.18% |
| Operating margin | 3.59% | 0.37% | 0.41% | 1.08% | -2.12% | 0.77% | 1.58% | 1.27% | 1.23% | 1.54% |
| Return on assets | 8.32% | 0.11% | 0.06% | 1.47% | -6.98% | 1.76% | 5.71% | 4.45% | 4.39% | 5.78% |
| Current ratio | 1.04 | 1.01 | 1.02 | 0.99 | 1.03 | 0.95 | 0.92 | 0.92 | 0.90 | 0.85 |

## As-reported value updates

2 tracked differences above grepcent's stated thresholds were found between the earliest XBRL-filed value and the value currently on file for the same fiscal period.

Ledger: /company/MCK/revisions/


## Quarterly

Quarterly standardized facts from SEC companyfacts as of latest extracted filing date 2026-08-05. Source: https://data.sec.gov/api/xbrl/companyfacts/CIK0000927653.json.

Flow metrics use discrete quarter-length periods from 10-Q/10-Q/A filings. Q4 revenue and net income are derived only when annual FY and nine-month YTD facts exist for the same fiscal year; derived Q4 values are labeled. EPS Q4 is not derived.

| Quarter | End date | Revenue | Net income | Diluted EPS | Method |
| --- | --- | ---: | ---: | ---: | --- |
| 2023-Q2 | 2022-09-30 |  |  | 6.42 | reported discrete quarter |
| 2023-Q3 | 2022-12-31 |  |  | 7.66 | reported discrete quarter |
| 2024-Q1 | 2023-06-30 |  |  | 7.02 | reported discrete quarter |
| 2024-Q2 | 2023-09-30 | 77,215,000,000 | 664,000,000 | 4.92 | reported discrete quarter |
| 2024-Q3 | 2023-12-31 | 80,898,000,000 | 589,000,000 | 4.42 | reported discrete quarter |
| 2024-Q4 | 2024-03-31 | 76,355,000,000 | 791,000,000 |  | derived Q4 = FY annual - nine-month YTD |
| 2025-Q1 | 2024-06-30 | 79,283,000,000 | 915,000,000 | 7.00 | reported discrete quarter |
| 2025-Q2 | 2024-09-30 | 93,651,000,000 | 241,000,000 | 1.87 | reported discrete quarter |
| 2025-Q3 | 2024-12-31 | 95,294,000,000 | 879,000,000 | 6.95 | reported discrete quarter |
| 2025-Q4 | 2025-03-31 | 90,823,000,000 | 1,260,000,000 |  | derived Q4 = FY annual - nine-month YTD |
| 2026-Q1 | 2025-06-30 | 97,827,000,000 | 784,000,000 | 6.25 | reported discrete quarter |
| 2026-Q2 | 2025-09-30 | 103,150,000,000 | 1,110,000,000 | 8.92 | reported discrete quarter |
| 2026-Q3 | 2025-12-31 | 106,158,000,000 | 1,186,000,000 | 9.59 | reported discrete quarter |
| 2026-Q4 | 2026-03-31 | 96,295,000,000 | 1,682,000,000 |  | derived Q4 = FY annual - nine-month YTD |
| 2027-Q1 | 2026-06-30 | 105,380,000,000 | 614,000,000 | 5.15 | reported discrete quarter |

## Filed narrative (10-K & 10-Q)

## Business

Verbatim Item 1 Business section from MCK's latest 10-K: [/company/MCK/business/](/company/MCK/business/).

## Risk Factors

Verbatim Item 1A Risk Factors from MCK's latest 10-K: [/company/MCK/risk-factors/](/company/MCK/risk-factors/).

## Latest quarter (10-Q)

Latest 10-Q source: https://www.sec.gov/Archives/edgar/data/927653/000092765326000234/mck-20260630.htm

Extracted structurally from real Item 2 body heading to real Item 3/4 boundary.
Confidence: high
Filing date: 2026-08-05
Report date: 2026-06-30

Item 2.    Management’s Discussion and Analysis of Financial Condition and Results of Operations.

INDEX TO MANAGEMENT’S DISCUSSION AND ANALYSIS

[[GREPCENT_TABLE]]
[["Section","Page"],["General","34"],["Overview of our Business","34"],["Executive Summary","35"],["Trends and Uncertainties","36"],["Overview of Consolidated Results","37"],["Overview of Segment Results","41"],["New Accounting Pronouncements","43"],["Financial Condition, Liquidity, and Capital Resources","44"],["Cautionary Notice About Forward-Looking Statements","48"],["Available Information","48"]]
[[/GREPCENT_TABLE]]

GENERAL

Management’s discussion and analysis of financial condition and results of operations, referred to as the “Financial Review,” is intended to assist the reader in the understanding and assessment of significant changes and trends related to the results of operations and financial position of McKesson Corporation together with its subsidiaries (collectively, the “Company,” “McKesson,” “we,” “our,” or “us,” and other similar pronouns). This discussion and analysis should be read in conjunction with the condensed consolidated financial statements and accompanying financial notes in Item 1 of Part I of this Quarterly Report on Form 10-Q (“Quarterly Report”) and in Item 8 of Part II of our Annual Report on Form 10-K for the fiscal year ended March 31, 2026 previously filed with the Securities and Exchange Commission (the “SEC”) on May 8, 2026 (“2026 Annual Report”).

Our fiscal year begins on April 1 and ends on March 31. Unless otherwise noted, all references to a particular year refer to our fiscal year.

Certain statements in this report constitute forward-looking statements. See “Cautionary Notice About Forward-Looking Statements” included in this Quarterly Report.

Overview of Our Business:

We are a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere. Our teams partner with biopharma companies, care providers, pharmacies, manufacturers, governments, and others to deliver insights, products, and services to help make quality care more accessible and affordable.

We implemented a new segment reporting structure commencing in the second quarter of fiscal 2026, which resulted in four reportable segments: North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions, and Medical-Surgical Solutions. Our former Norwegian operations were included in Other. All prior segment information has been recast to reflect our new segment structure and current period presentation. Our organizational structure also includes Corporate, which consists of income and expenses associated with administrative functions and projects, as well as the results of certain investments. The factors for determining the reportable segments include the manner in which management evaluates the performance of the Company combined with the nature of individual business activities. We evaluate the performance of our reportable segments on a number of measures, including revenues and operating profit before interest expense and income taxes.

34

[[GREPCENT_TABLE]]
[["Table of Contents","MD&A Index"]]
[[/GREPCENT_TABLE]]
McKESSON CORPORATION

FINANCIAL REVIEW (CONTINUED)

(UNAUDITED)

The following summarizes our four reportable segments. Refer to Financial Note 13, “Segments of Business,” to the accompanying condensed consolidated financial statements included in this Quarterly Report for further information regarding our reportable segments.

•North American Pharmaceutical segment provides distribution and logistics services for branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs along with other healthcare-related products to customers in the United States (“U.S.”) and Canada. In addition, the segment sells financial, operational, and clinical solutions to pharmacies (retail, hospital, alternate sites) and provides consulting, outsourcing, technological, and other services.

•Oncology & Multispecialty segment includes provider solutions that encompass specialty drug distribution, group purchasing organizations, infusion services, direct to patient pharmacy capabilities, cell and gene therapy services with InspiroGene, technology solutions, practice consulting services, and vaccine distribution. In addition, the segment supports The U.S. Oncology Network, one of the largest networks of physician-led, integrated, community-based oncology practices dedicated to advancing high-quality, evidence-based cancer care in the U.S., and includes PRISM Vision Holdings, LLC (“PRISM Vision”), which drives patient outcomes in a retina and ophthalmology setting. Combined with Sarah Cannon Research Institute and our technology business, Ontada, this segment provides research, insights, technologies, and services that address and improve cancer and specialty care.

•Prescription Technology Solutions segment combines automation and our ability to navigate the healthcare ecosystem to connect patients, pharmacies, providers, pharmacy benefit managers, health plans, and biopharma companies to address patients’ medication access, affordability, and adherence challenges. Prescription Technology Solutions offers technology services, which includes electronic prior authorization, prescription price transparency, benefit insight, dispensing support services, and patient enrollment, in addition to third-party logistics, and wholesale distribution support across various therapeutic categories and temperature ranges to biopharma customers throughout the product lifecycle.

•Medical-Surgical Solutions segment provides medical-surgical, laboratory, and pharmaceutical distribution, logistics, and other services to U.S. healthcare providers operating in the non-acute settings. These include ambulatory care environments, such as physician offices, surgery centers, and hospital reference labs, as well as extended care settings, including nursing homes, hospice and home health care agencies, government facilities, and online marketplaces and retailers. This segment offers national brand medical-surgical products as well as our own line of more than 4,000 high-quality products through a network of distribution centers within the U.S. During fiscal 2026, we announced our intention to separate this segment into an independent company. As a part of the separation strategy, on June 1, 2026, we completed a transaction under which funds managed by affiliates of Apollo Global Management, Inc. (“Apollo Funds”) acquired an approximately 13% minority ownership interest in our Medical‑Surgical Solutions segment through an investment of approximately $1.25 billion in the segment’s convertible preferred equity. We recognized a redeemable noncontrolling interest associated with the divested portion of the Medical‑Surgical Solutions segment. We retain operating control and majority ownership of Medical-Surgical Solutions and continue to consolidate this segment into our consolidated financial statements.

Executive Summary:

The following summary provides highlights and key factors that impacted our business, operating results, financial condition, and liquidity for the three months ended June 30, 2026, as well as other material developments:

•For the three months ended June 30, 2026 compared to the prior year, revenues increased by 8%, gross profit increased by 12%, total operating expenses increased by 5%, and other income, net increased by 3%. Refer to the “Overview of Consolidated Results” section below for an analysis of these changes;

•Diluted earnings per common share attributable to McKesson Corporation decreased to $5.15 from $6.25 for the three months ended June 30, 2026 compared to the respective prior year period;

•In the first quarter of 2027, certain of our subsidiaries within the Medical-Surgical Solutions segment entered into, and then amended, a syndicated credit agreement for: a $750 million principal senior secured term loan due in 2031, a $250 million principal senior secured term loan due in 2028; a $2.25 billion senior secured term loan due 2032, for total proceeds received, net of discounts and debt offering expenses, of $3.2 billion; and a $1.0 billion senior secured revolving credit facility scheduled to mature in April 2031. Refer to Financial Note 8, “Debt and Financing Activities,” to the accompanying condensed consolidated financial statements in this Quarterly Report for additional information;

35

[[GREPCENT_TABLE]]
[["Table of Contents","MD&A Index"]]
[[/GREPCENT_TABLE]]
McKESSON CORPORATION

FINANCIAL REVIEW (CONTINUED)

(UNAUDITED)

•On April 24, 2026, we terminated our 2022 revolving credit facility and our 364-Day credit facility and entered into a new Credit Agreement (the “2026 Credit Facility”) that provides a syndicated $5.0 billion senior unsecured credit facility. The 2026 Credit Facility matures in 2031. Refer to Financial Note 8, “Debt and Financing Activities,” to the accompanying condensed consolidated financial statements in this Quarterly Report for additional information;

•As a part of our intention to separate our Medical-Surgical Solutions business into an independent company, on June 1, 2026, Apollo Funds invested approximately $1.25 billion for convertible preferred equity of Medical-Surgical Solutions business to acquire an approximately 13% interest in the business;

•On April 29, 2026, our Board of Directors (the “Board”) approved the Company to repurchase up to an additional $5.0 billion shares of common stock;

•During the three months ended June 30, 2026, we returned $2.6 billion of cash to shareholders through $2.5 billion of common stock repurchases and $102 million of dividend payments. The total remaining authorization outstanding for repurchases of the Company’s common stock at June 30, 2026 was $5.2 billion; and

•On July 21, 2026, the Board raised our quarterly dividend from $0.82 to $0.94 per share of common stock.

Trends and Uncertainties:

Government Policies

As described in “Item 1. Government Regulation” and “Item 1A - Risk Factors” in Part I of our 2026 Annual Report, our industry is highly regulated and is subject to risks and uncertainty caused by the volume and speed of changes to regulatory policies. Changes in regulatory posture and law may result in significant changes in healthcare policy, government funding of healthcare costs, and other laws affecting our operations, but the ultimate outcomes are difficult to predict.

36

[[GREPCENT_TABLE]]
[["Table of Contents","MD&A Index"]]
[[/GREPCENT_TABLE]]
McKESSON CORPORATION

FINANCIAL REVIEW (CONTINUED)

(UNAUDITED)

RESULTS OF OPERATIONS

Overview of Consolidated Results:

[[GREPCENT_TABLE]]
[["(Dollars in millions, except per share data)","Three Months Ended June 30,"],["2026","","2025","","Change"],["Revenues","$","105,380","","","$","97,827","","","8","","%"],["Gross profit","3,685","","","3,279","","","12"],["Gross profit margin","3.50","","%","3.35","","%","15","","bp"],["Total operating expenses","$","(2,366)","","","$","(2,243)","","","5","","%"],["Total operating expenses as a percentage of revenues","2.25","","%","2.29","","%","(4)","","bp"],["Other income, net","$","66","","","$","64","","","3","","%"],["Interest expense","(77)","","","(49)","","","57"],["Income before income taxes","1,308","","","1,051","","","24"],["Income tax expense","(276)","","","(220)","","","25"],["Reported income tax rate","21.1","","%","20.9","","%","20","","bp"],["Net income","1,032","","","831","","","24"],["Net income attributable to noncontrolling interests","(418)","","","(47)","","","789"],["Net income attributable to McKesson Corporation","$","614","","","$","784","","","(22)","","%"],["Diluted earnings per common share attributable to McKesson Corporation","$","5.15","","","$","6.25","","","(18)","","%"],["Weighted-average diluted common shares outstanding","119.2","","","125.5","","","(5)","","%"]]
[[/GREPCENT_TABLE]]

Any percentage chan

[Excerpt truncated for page length; source filing is linked above.]

## Latest 10-K MD&A (excerpt)

Latest 10-K Item 7 source: https://www.sec.gov/Archives/edgar/data/927653/000092765326000069/mck-20260331.htm
Complete FY 2026 MD&A: /company/MCK/mda/fy2026/

Extracted structurally from real Item 7 body heading to real Item 7A/8 boundary.
Confidence: high
Filing date: 2026-05-08
Report date: 2026-03-31

Item 7.    Management’s Discussion and Analysis of Financial Condition and Results of Operations.

INDEX TO MANAGEMENT’S DISCUSSION AND ANALYSIS

[[GREPCENT_TABLE]]
[["Section","Page"],["General","33"],["Overview of Our Business","33"],["Executive Summary","35"],["Trends and Uncertainties","36"],["Overview of Consolidated Results","37"],["Overview of Segment Results","42"],["Foreign Operations","45"],["Business Combinations","45"],["Fiscal 2027 Outlook","45"],["Critical Accounting Estimates","46"],["Financial Condition, Liquidity, and Capital Resources","51"],["Related Party Balances and Transactions","56"],["New Accounting Pronouncements","56"]]
[[/GREPCENT_TABLE]]

GENERAL

Management’s discussion and analysis of financial condition and results of operations, referred to as the “Financial Review,” is intended to assist the reader in the understanding and assessment of significant changes and trends related to the results of operations and financial position of McKesson Corporation together with its subsidiaries (collectively, the “Company,” “McKesson,” “we,” “our,” or “us” and other similar pronouns). This discussion and analysis should be read in conjunction with the consolidated financial statements and accompanying financial notes in Item 8 of Part II of this Annual Report on Form 10-K (“Annual Report”).

Our fiscal year begins on April 1 and ends on March 31. Unless otherwise noted, all references to a particular year refer to our fiscal year.

Our Financial Review within this Annual Report generally discusses fiscal 2026 and fiscal 2025 results and year-over-year comparisons between fiscal 2026 and fiscal 2025. For a discussion of our year-over-year comparisons between fiscal 2025 and fiscal 2024, refer to Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations of Part II of our Annual Report on Form 10-K for the year ended March 31, 2025, previously filed with the Securities and Exchange Commission on May 9, 2025.

Certain statements in this Annual Report constitute forward-looking statements. See Item 1 - Business - Forward-Looking Statements in Part I of this Annual Report for additional factors relating to these statements and Item 1A - Risk Factors in Part I of this Annual Report for a list of certain risk factors applicable to our business, financial condition and liquidity, and results of operations.

Overview of Our Business:

We are a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere. Our teams partner with biopharma companies, care providers, pharmacies, manufacturers, governments, and others to deliver insights, products, and services to help make quality care more accessible and affordable.

We implemented a new segment reporting structure commencing in the second quarter of fiscal 2026, which resulted in four reportable segments: North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions, and

33

[[GREPCENT_TABLE]]
[["Table of Contents","MD&A Index"]]
[[/GREPCENT_TABLE]]

McKESSON CORPORATION

FINANCIAL REVIEW (Continued)

Medical-Surgical Solutions. Our former Norwegian operations were included in Other. All prior segment information has been recast to reflect our new segment structure and current period presentation. Our organizational structure also includes Corporate, which consists of income and expenses associated with administrative functions and projects, as well as the results of certain investments. The factors for determining the reportable segments include the manner in which management evaluates the performance of the Company combined with the nature of individual business activities. We evaluate the performance of our operating segments on a number of measures, including revenues and operating profit before interest expense and income taxes.

The following summarizes our four reportable segments. Refer to Financial Note 20, “Segments of Business,” to the consolidated financial statements included in this Annual Report for further information regarding our reportable segments.

•North American Pharmaceutical segment provides distribution and logistics services for branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs along with other healthcare-related products to customers in the United States (“U.S.”) and Canada. In addition, the segment sells financial, operational, and clinical solutions to pharmacies (retail, hospital, alternate sites) and provides consulting, outsourcing, technological, and other services. The U.S. distribution operations were previously included in the former U.S. Pharmaceutical reportable segment and the Canadian operations were previously included in the former International reportable segment.

•Oncology & Multispecialty segment includes provider solutions that encompass specialty drug distribution, group purchasing organizations, infusion services, direct to patient pharmacy capabilities, cell and gene therapy services with InspiroGene, technology solutions, practice consulting services, and vaccine distribution. In addition, the segment supports the U.S. Oncology Network, one of the largest networks of physician-led, integrated, community-based oncology practices dedicated to advancing high-quality, evidence-based cancer care in the U.S., and includes PRISM Vision Holdings, LLC (“PRISM Vision”), which drives patient outcomes in a retina and ophthalmology setting. Combined with Sarah Cannon Research Institute and our technology business, Ontada, this segment provides research, insights, technologies, and services that address and improve cancer and specialty care. This segment was previously reflected in the former U.S. Pharmaceutical reportable segment.

•Prescription Technology Solutions segment combines automation and our ability to navigate the healthcare ecosystem to connect patients, pharmacies, providers, pharmacy benefit managers, health plans, and biopharma companies to address patients’ medication access, affordability, and adherence challenges. Prescription Technology Solutions offers technology services, which includes electronic prior authorization, prescription price transparency, benefit insight, dispensing support services, and patient enrollment, in addition to third-party logistics, and wholesale distribution support across various therapeutic categories and temperature ranges to biopharma customers throughout the product lifecycle.

•Medical-Surgical Solutions segment provides medical-surgical, laboratory, and pharmaceutical distribution, logistics, and other services to U.S. healthcare providers operating in the non-acute settings. These include ambulatory care environments, such as physician offices, surgery centers, and hospital reference labs, as well as extended care settings, including nursing homes, hospice and home health care agencies, government facilities, and online marketplaces and retailers. This segment offers national brand medical-surgical products as well as our own line of more than 4,000 high-quality products through a network of distribution centers within the U.S. During fiscal 2026, we announced our intention to separate this segment into an independent company. As a part of the separation strategy, on April 20, 2026, we announced a definitive agreement under which funds managed by affiliates of Apollo Global Management, Inc. (“Apollo Funds”) will acquire approximately 13% minority ownership interest in our Medical‑Surgical Solutions segment through an investment of approximately $1.25 billion in the segment’s convertible preferred equity. The transaction is subject to regulatory approvals and customary closing conditions.

Our former Norwegian operations, which provided distribution and services to wholesale and retail customers in Norway where we owned, partnered, or franchised with retail pharmacies, were included in Other. During fiscal 2026, we completed the transaction to sell our businesses in Norway (“Norway disposal group”). This divestiture is further described in the “Business Acquisitions and Divestitures” section below.

34

[[GREPCENT_TABLE]]
[["Table of Contents","MD&A Index"]]
[[/GREPCENT_TABLE]]

McKESSON CORPORATION

FINANCIAL REVIEW (Continued)

Business Acquisitions and Divestitures

Norwegian Divestiture Activities

On January 30, 2026, we completed the sale of our Norway disposal group for an adjusted purchase price of $821 million. We recorded a net gain of $480 million for the year ended March 31, 2026 in total operating expenses. The gain includes a $164 million loss related to the accumulated other comprehensive loss balances associated with the disposal group.

PRISM Vision Holdings, LLC

On April 1, 2025, we completed the acquisition of a controlling interest in PRISM Vision, a leading provider of general ophthalmology and retina administrative services. We acquired an 80% interest in PRISM Vision for $875 million in cash, and prior owners, including management and physicians in PRISM Vision practices, retained a 20% ownership interest. As of the acquisition date, the financial results of PRISM Vision are reported within our Oncology & Multispecialty segment.

Community Oncology Revitalization Enterprise Ventures, LLC

On June 2, 2025, we completed the acquisition of a controlling interest in Community Oncology Revitalization Enterprise Ventures, LLC (“Core Ventures”), a business and administrative services organization established by Florida Cancer Specialists & Research Institute, LLC, (“FCS”). We acquired a 70% controlling interest in Core Ventures for $2.5 billion in cash and FCS physicians retained a 30% ownership interest. As of the acquisition date, Core Ventures is a part of the Oncology platform and financial results are reported within our Oncology & Multispecialty segment.

Refer to Financial Note 2, “Business Acquisitions and Divestitures,” to the consolidated financial statements included in this Annual Report for additional information regarding these transactions.

Executive Summary:

The following summary provides highlights and key factors that impacted our business, operating results, financial condition, and liquidity for the year ended March 31, 2026:

•For the year ended March 31, 2026 compared to the prior year, revenues increased by 12%, gross profit increased by 9%, total operating expenses decreased by 6%, and other income, net increased by 17%. Refer to the “Overview of Consolidated Results” section below for an analysis of these changes;

•Diluted earnings per common share attributable to McKesson Corporation increased to $38.38 in fiscal 2026 from $25.72 in the prior year;

•For the year ended March 31, 2026, we recorded restructuring charges of $170 million related to an enterprise-wide initiative to drive operational efficiencies as further described in the “Restructuring Initiatives” section of “Overview of Consolidated Results” below;

•On April 1, 2025, we completed the acquisition of a controlling interest in PRISM Vision for $875 million in cash, as discussed in further detail in the “Business Acquisitions and Divestitures” section above;

•On May 8, 2025, we entered into a syndicated $1.0 billion 364-Day senior unsecured credit facility (the “364-Day Credit Facility”) that was scheduled to mature in May 2026 but was terminated on April 24, 2026 and replaced with the 2026 5-Year Facility described in the “Recent Developments” section below. Refer to Financial Note 11, “Debt and Financing Activities,” to the consolidated financial statements included in this Annual Report for additional information;

•On May 30, 2025, we completed a public debt offering of 4.65% Notes due May 30, 2030 in a principal amount of $650 million, 4.95% Notes due May 30, 2032 in a principal amount of $650 million, and 5.25% Notes due May 30, 2035 in a principal amount of $700 million, for total proceeds received, net of discounts and debt offering expenses, of 2.0 billion. The net p

[Excerpt truncated for page length; the complete text is on the linked full-MD&A page.]

Read the full FY 2026 MD&A: /company/MCK/mda/fy2026/
All MD&A years: /company/MCK/mda/


## MD&A history

Prior-year 10-K MD&A spans are extracted from SEC filings with the same bounded parser used for the latest filing. Each year's full verbatim text is on its own sub-page.

- [FY 2025 MD&A](/company/MCK/mda/fy2025/): filed 2025-05-09; accession 0000927653-25-000036 (https://www.sec.gov/Archives/edgar/data/927653/000092765325000036/mck-20250331.htm)
- [FY 2024 MD&A](/company/MCK/mda/fy2024/): filed 2024-05-08; accession 0000927653-24-000035 (https://www.sec.gov/Archives/edgar/data/927653/000092765324000035/mck-20240331.htm)
- [FY 2023 MD&A](/company/MCK/mda/fy2023/): filed 2023-05-09; accession 0000927653-23-000038 (https://www.sec.gov/Archives/edgar/data/927653/000092765323000038/mck-20230331.htm)
- [FY 2022 MD&A](/company/MCK/mda/fy2022/): filed 2022-05-09; accession 0000927653-22-000051 (https://www.sec.gov/Archives/edgar/data/927653/000092765322000051/mck-20220331.htm)


## FDA-approved drug applications

Applications listed under this company's exact-matched sponsor name. Approved applications only.

No resolved FDA applications were found for this company under the exact-unique, approved-only publish rule.

Sponsor as listed in Drugs@FDA at retrieval (2026-08-07); FDA sponsor listings can lag ownership transfers.

This list covers FDA applications whose listed sponsor name maps to this company by an exact-unique match; applications listed under sponsor names not mapped to this company (subsidiaries, name variants, joint ventures) are absent.


## Macro cross-references

Indicators mapped to this company's SIC classification (industry 5122 Wholesale-Drugs, Proprietaries & Druggists' Sundries) by grepcent's deterministic macro-sector crosswalk. A navigational mapping, not a statistical or causal claim.

- [PCE](/indicator/PCE/): Personal Consumption Expenditures
- [RSAFS](/indicator/RSAFS/): Advance Retail Sales: Retail Trade
- [BOPGSTB](/indicator/BOPGSTB/): U.S. International Trade in Goods and Services: Balance
- [DGS10](/indicator/DGS10/): Market Yield on U.S. Treasury Securities at 10-Year Constant Maturity

Macro-to-micro threads including this sector: [Money & trade](/thread/money-trade/), [Industrial orders & inventories](/thread/industrial-orders/), [Trade & external](/thread/trade-external/).

All macro indicators: /indicators/


## For LLMs & downloads

Markdown twin: /company/MCK.md · JSON record: /company/MCK.json · verified financials: /company/MCK/financials.json / /company/MCK/financials.csv · machine TOC for the whole site: /llms.txt